No matter how tough you think your hands are, gloves protect more than your skin from becoming rough. Without protection, ...

Stent noted that despite Nestle (NSE:NEST)’s tendency to fare well in risk-averse market environments, with a conservative beta of 0.42, the recent significant re-rating of the company’s ...

Similarly, Leerink Partners cut their price target to $1.00 from $3.00, maintaining a Market Perform rating, after Ironwood announced the need for an additional Phase 3 trial for apraglutide. The ...

Stent noted that despite Nestle (NSE:NEST)’s tendency to fare well in risk-averse market environments, with a conservative beta of 0.42, the recent significant re-rating of the company’s price ...

On Monday, Deutsche Bank (ETR:DBKGn) analysts adjusted their stance on Elia Group SA (ELI:BB), shifting the stock rating from Buy to Hold and revising the price target to €85.00, a slight decrease ...

To help combat this, J. J. Keller & Associates Inc. is introducing new cut-resistant gloves and offering a free cut glove resource to help employers prevent injuries. J.J. Keller's offerings Safety ...

— We have everything you need: full data on over 800 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & ...

JPMorgan (NYSE:JPM), on the other hand, raised its price target to $34, citing strong operational results and higher-than-expected natural gas pricing, despite maintaining an Underweight rating. The ...

On Wednesday, RBC Capital Markets adjusted its stance on Beacon Roofing Supply (NASDAQ:BECN) (market cap: $7.65 billion), downgrading the company’s stock rating from Outperform to Sector Perform. The ...

These standards use numerical ratings to indicate the glove’s ability to withstand sharp objects. The ANSI system, for example, uses a scale from A1 to A9, with A1 offering the least protection and A9 ...

According to a real-world study, cenobamate was effective in patients with drug-resistant epilepsy (DRE), with 49.3% of patients achieved a 50% or greater reduction in seizure frequency at 3 months.